Core Points - bioAffinity Technologies, Inc. has entered into warrant exercise agreements with three accredited investors to exercise existing warrants for a total of 1,041,667 shares, generating approximately $1,302,083 in gross cash proceeds [1] - The exercise price of the existing warrants has been reduced from $1.64 to $1.25 per share, and new unregistered warrants have been issued for 1,302,083 shares at an exercise price of $1.50 per share [1] - A securities purchase agreement has been established for the purchase of 360,000 shares in a registered direct offering, along with private warrants for 450,000 shares at a combined purchase price of $1.25 [2] - The gross proceeds from the offering are expected to be around $450,000, excluding potential proceeds from the exercise of the private warrants [3] Company Actions - The closing of the offering is anticipated to occur on or about August 5, 2024, pending customary closing conditions [3] - WallachBeth Capital LLC is acting as the sole placement agent for the registered direct offering and private placement, as well as the financial advisor for the warrant inducement transaction [4] - The common stock will be issued under an effective shelf registration statement previously filed with the SEC, and the private warrants will be offered under an exemption from registration requirements [5]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 July 9, 2024 Date of Report (Date of earliest event reported) Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.007 per share BIAF The Nasdaq Stock Market LLC Tradeable Warrants to purchase Common Stock BIAFW The Nasdaq Stock Market LLC 22211 W Interstate 10 Suite 1206 San Antonio, Texas 78257 (210) 698-5334 (Address of principal executive offices and Registrant's telephone number ...

News Release More than 547% annualized growth rate for CyPath Lung orders in first four months of 2024 over full-year 2023, leading to 35% increase in original 2024 forecast Key Highlights "CyPath Lung is positioned to set a new standard in the early detection of lung cancer – a market projected to reach $4.7 billion by 2030," Zannes continued. "As we continue to scale our operations and enhance our offerings, our focus remains steadfast on improving patient outcomes and delivering shareholder value. With M ...

Financial Performance - Net revenue for the three months ended March 31, 2024, was $2,406,391, compared to $921 for the same period in 2023, representing a significant increase[78] - Total operating expenses for the same period were $4,351,621, up from $1,558,891 in 2023, indicating a rise of approximately 179%[78] - The net loss for the three months ended March 31, 2024, was $1,961,815, compared to a net loss of $1,532,790 in 2023, reflecting an increase in losses[78] - For the three months ended March 31, 2024, the net loss was $1,961,815, compared to a net loss of $1,532,790 for the same period in 2023, representing an increase of approximately 28%[80] - The company reported a total cash used in operating activities of $2,345,975 for the three months ended March 31, 2024, compared to $1,529,041 for the same period in 2023, reflecting a 53% increase[80] Assets and Liabilities - Cash and cash equivalents decreased to $2,453,165 as of March 31, 2024, down from $2,821,570 at December 31, 2023, a decline of about 13%[76] - Total assets as of March 31, 2024, were $8,049,266, a decrease from $8,221,552 at December 31, 2023, representing a reduction of approximately 2.1%[76] - Total liabilities decreased to $2,792,215 as of March 31, 2024, from $3,366,297 at December 31, 2023, indicating a decline of about 17%[76] - The company’s accumulated deficit increased to $(46,566,294) as of March 31, 2024, from $(44,604,479) at December 31, 2023[76] - The company’s total stockholders' equity increased to $5,257,051 as of March 31, 2024, from $4,855,255 at December 31, 2023, reflecting an increase of approximately 8.3%[76] Shareholder Information - The company reported a weighted average of 9,915,426 common shares outstanding for the three months ended March 31, 2024, compared to 8,433,689 in 2023, an increase of approximately 17.6%[78] - The balance of common shares outstanding increased from 8,463,052 as of March 31, 2023, to 11,216,491 as of March 31, 2024, marking an increase of approximately 32.7%[79] - The company issued 1,600,000 shares of Common Stock in a registered direct offering, generating aggregate gross proceeds of $2.5 million[133] - The company has authorized a total of 25,000,000 shares of Common Stock, with 11,514,354 shares issued as of March 31, 2024[119] Expenses - Research and development expenses for the three months ended March 31, 2024, were $393,639, compared to $369,617 in 2023, showing a slight increase of about 6.5%[78] - Stock-based compensation expense for the three months ended March 31, 2024, was $283,712, up from $157,613 in the same period of 2023, indicating an increase of about 80%[80] - Advertising expenses increased to $11,920 for the three months ended March 31, 2024, compared to $6,049 for the same period in 2023, reflecting a 97.5% increase[112] Acquisitions and Growth Strategy - The company completed an acquisition of Village Oaks for a total consideration of $3,500,000, which included $2.5 million in cash and 564,972 shares of common stock valued at $1 million[107] - Goodwill recognized from the acquisition of Village Oaks amounted to $1,404,000, reflecting the excess fair value after allocation to identifiable net assets[88] - The company recognized revenue from the CyPath Lung diagnostic test, which is expected to increase following the acquisition of Village Oaks Pathology Services[136] - The company is focused on developing proprietary noninvasive diagnostic tests for early-stage cancer detection, with its first product, CyPathLung, already offered for sale[82] - The company expects to continue incurring significant operating losses as it develops its diagnostic tests and advances them through clinical trials[136] Financial Risks - The company has significant cash balances that regularly exceed the federally insured limit of $250,000, which could impact its financial condition if access to these funds is restricted[111] - The company plans to expand its organization to accommodate potential growth and retain key personnel, which is critical for its operational strategy[95] Options and Warrants - The company had 8,838,717 warrants outstanding as of March 31, 2024, with a weighted average exercise price of $3.53[123] - The company exercised 64,848 options at an exercise price of $1.155, generating proceeds of $74,899 during the three months ended March 31, 2024[147] - As of March 8, 2024, there were 1,601,259 tradeable warrants and 2,704,554 non-tradeable warrants outstanding[151]

As filed with the Securities and Exchange Commission on April 4, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) | Delaware | 8731 | 46-5211056 | | --- | --- | --- | | (State or other jurisdiction of | (Primary Standard Industrial | (I.R.S. Employer | | incorporation or organization) | Classification Code Nu ...

CyPathLung has not been tested directly against its competitors' products, but a comparison of the published performance numbers suggests CyPath Lung is among the highest performing tests on the market. Furthermore, CyPath Lung is noninvasive – not even requiring a needle stick – and cost effective, and processing and analysis procedures are easy to perform. 11 Published data and the results of clinical trials allow us to group lung cancer diagnostic tests into three categories: (1) balanced tests;( 2) rule ...

1 bioAffinity Technologies Reports Fourth Quarter and Full Year 2023 Financial Results ● Reported fiscal year 2023 revenue of $2.5 million, a significant increase from $5,000 in 2022, driven by the September 2023 acquisition of Precision Pathology Laboratory Services (PPLS) and increasing sales of CyPath Lung, the Company's noninvasive test to detect early-stage lung cancer. ● Achieved a milestone with the Centers for Medicare and Medicaid Services (CMS) final determination for payment for CyPath Lung for t ...

JERSEY CITY, N.J., March 8, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc. (Nasdaq: BIAF and BIAFW) has closed a securities purchase agreement with institutional investors for the purchase and sale of 1,600,000 shares of common stock in a registered direct offering and common warrants to purchase up to 1,600,000 shares of common stock in a concurrent private placement (together with ...

SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (Nasdaq: BIAF and BIAFW) today announced it has closed a securities purchase agreement with institutional investors for the purchase and sale of 1,600,000 shares of common stock in a registered direct offering and common warrants to purchase up to 1,600,000 shares of common stock in a concurrent private placement (together with the registered direct offering) at a combined purchase price of $1.5625 per common share. The common warrants issued purs ...

JERSEY CITY, N.J., March 6, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that BioAffinity Technologies (NASDAQ: BIAF; BIAFW) has entered into a securities purchase agreement with institutional investors for the purchase and sale of 1,600,000 shares of common stock in a registered direct offering and common warrants to purchase up to 1,600,000 shares of common stock in a concurrent private placement (together with th ...